“…The management of CHB is complex and the decision to start viral suppression therapy is dependent on clinical factors including HBV DNA levels, liver inflammation, and/or fibrosis. In this issue of the Saudi Journal of Gastroenterology, Sanai et al [ 1 ] retrospectively evaluated CHB patients with negative HBe antigen and fluctuating HBV DNA levels (2000 to 20000 IU/mL) vs those without fluctuation (persistently below 2000 IU/mL), comparing their risk of developing of significant hepatic fibrosis. They observed no significant association with HBV DNA levels and liver fibrosis.…”